Johnson & Johnson (NYSE:JNJ) Shares Sold by Citizens Financial Group Inc RI

Citizens Financial Group Inc RI trimmed its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 81,623 shares of the company’s stock after selling 831 shares during the quarter. Citizens Financial Group Inc RI’s holdings in Johnson & Johnson were worth $14,419,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of JNJ. Glassy Mountain Advisors Inc. acquired a new position in Johnson & Johnson in the 4th quarter valued at about $35,000. Retirement Financial Solutions LLC acquired a new position in Johnson & Johnson in the 4th quarter valued at about $40,000. TD Capital Management LLC acquired a new position in Johnson & Johnson in the 3rd quarter valued at about $48,000. VitalStone Financial LLC acquired a new position in Johnson & Johnson in the 4th quarter valued at about $52,000. Finally, Iron Horse Wealth Management LLC lifted its holdings in shares of Johnson & Johnson by 112.8% in the 4th quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock worth $53,000 after acquiring an additional 159 shares during the last quarter. 67.94% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 0.3 %

JNJ stock opened at $158.91 on Monday. Johnson & Johnson has a one year low of $150.11 and a one year high of $183.35. The stock has a market capitalization of $412.96 billion, a PE ratio of 33.24, a price-to-earnings-growth ratio of 2.71 and a beta of 0.53. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.85 and a current ratio of 1.07. The company has a fifty day moving average of $159.70 and a 200-day moving average of $166.20.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its earnings results on Tuesday, April 18th. The company reported $2.68 EPS for the quarter, topping the consensus estimate of $2.51 by $0.17. The company had revenue of $24.75 billion during the quarter, compared to analysts’ expectations of $23.61 billion. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The business’s revenue was up 5.6% on a year-over-year basis. During the same quarter last year, the business earned $2.67 EPS. As a group, analysts expect that Johnson & Johnson will post 10.66 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 6th. Stockholders of record on Tuesday, May 23rd will be issued a $1.19 dividend. This represents a $4.76 dividend on an annualized basis and a dividend yield of 3.00%. The ex-dividend date of this dividend is Monday, May 22nd. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s dividend payout ratio (DPR) is currently 94.56%.

Insider Activity

In other news, insider James D. Swanson sold 1,062 shares of the stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the completion of the transaction, the insider now owns 9,215 shares in the company, valued at approximately $1,425,191.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Guggenheim assumed coverage on shares of Johnson & Johnson in a research note on Tuesday, February 28th. They set a “neutral” rating and a $161.00 target price on the stock. StockNews.com assumed coverage on shares of Johnson & Johnson in a research note on Thursday. They set a “strong-buy” rating on the stock. UBS Group assumed coverage on shares of Johnson & Johnson in a research report on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 price objective on the stock. Atlantic Securities dropped their price objective on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 19th. Finally, Piper Sandler dropped their target price on shares of Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $173.00.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.